Your browser doesn't support javascript.
loading
Correction to: Fludarabine and rituximab with escalating doses of lenalidomide followed by lenalidomide/rituximab maintenance in previously untreated chronic lymphocytic leukaemia (CLL): the REVLIRIT CLL-5 AGMT phase I/II study.
Egle, Alexander; Steurer, Michael; Melchardt, Thomas; Weiss, Lukas; Gassner, Franz Josef; Zaborsky, Nadja; Geisberger, Roland; Catakovic, Kemal; Hartmann, Tanja Nicole; Pleyer, Lisa; Voskova, Daniela; Thaler, Josef; Lang, Alois; Girschikofsky, Michael; Petzer, Andreas; Greil, Richard.
Afiliação
  • Egle A; Department of Internal Medicine III with Hematology and Medical Oncology, Oncologic Center, Paracelsus Medical University Salzburg, Müllner-Hauptstr. 48, 5020, Salzburg, Austria.
  • Steurer M; Salzburg Cancer Research Institute - Laboratory of Immunological and Molecular Cancer Research (SCRI-LIMCR) and Cancer Cluster Salzburg (CCS), Salzburg, Austria.
  • Melchardt T; Division of Hematology and Oncology, Laboratory for Molecular Genetics and Diagnostics, Innsbruck Medical University, Innsbruck, Austria.
  • Weiss L; Department of Internal Medicine III with Hematology and Medical Oncology, Oncologic Center, Paracelsus Medical University Salzburg, Müllner-Hauptstr. 48, 5020, Salzburg, Austria.
  • Gassner FJ; Salzburg Cancer Research Institute - Laboratory of Immunological and Molecular Cancer Research (SCRI-LIMCR) and Cancer Cluster Salzburg (CCS), Salzburg, Austria.
  • Zaborsky N; Department of Internal Medicine III with Hematology and Medical Oncology, Oncologic Center, Paracelsus Medical University Salzburg, Müllner-Hauptstr. 48, 5020, Salzburg, Austria.
  • Geisberger R; Salzburg Cancer Research Institute - Laboratory of Immunological and Molecular Cancer Research (SCRI-LIMCR) and Cancer Cluster Salzburg (CCS), Salzburg, Austria.
  • Catakovic K; Salzburg Cancer Research Institute - Laboratory of Immunological and Molecular Cancer Research (SCRI-LIMCR) and Cancer Cluster Salzburg (CCS), Salzburg, Austria.
  • Hartmann TN; Salzburg Cancer Research Institute - Laboratory of Immunological and Molecular Cancer Research (SCRI-LIMCR) and Cancer Cluster Salzburg (CCS), Salzburg, Austria.
  • Pleyer L; Salzburg Cancer Research Institute - Laboratory of Immunological and Molecular Cancer Research (SCRI-LIMCR) and Cancer Cluster Salzburg (CCS), Salzburg, Austria.
  • Voskova D; Salzburg Cancer Research Institute - Laboratory of Immunological and Molecular Cancer Research (SCRI-LIMCR) and Cancer Cluster Salzburg (CCS), Salzburg, Austria.
  • Thaler J; Salzburg Cancer Research Institute - Laboratory of Immunological and Molecular Cancer Research (SCRI-LIMCR) and Cancer Cluster Salzburg (CCS), Salzburg, Austria.
  • Lang A; Department of Internal Medicine III with Hematology and Medical Oncology, Oncologic Center, Paracelsus Medical University Salzburg, Müllner-Hauptstr. 48, 5020, Salzburg, Austria.
  • Girschikofsky M; Salzburg Cancer Research Institute - Laboratory of Immunological and Molecular Cancer Research (SCRI-LIMCR) and Cancer Cluster Salzburg (CCS), Salzburg, Austria.
  • Petzer A; Centre for Hematology and Medical Oncology, Kepler University Hospital, Linz, Austria.
  • Greil R; Department for Internal Medicine IV, Hospital Wels-Grieskirchen, Wels, Austria.
Ann Hematol ; 97(9): 1745, 2018 09.
Article em En | MEDLINE | ID: mdl-29934835
ABSTRACT
The original version of this article contained a mistake. The name of Tanja Nicole Hartman should have been Tanja Nicole Hartmann. The original article has been corrected.
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Revista: Ann Hematol Assunto da revista: HEMATOLOGIA Ano de publicação: 2018 Tipo de documento: Article País de afiliação: Áustria
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Revista: Ann Hematol Assunto da revista: HEMATOLOGIA Ano de publicação: 2018 Tipo de documento: Article País de afiliação: Áustria